RESEARCH ARTICLE

SCFβ-TRCP E3 ubiquitin ligase targets the tumor suppressor ZNRF3 for ubiquitination and degradation

  • Yanpeng Ci 1,2 ,
  • Xiaoning Li 2,3 ,
  • Maorong Chen 4 ,
  • Jiateng Zhong 2,5 ,
  • Brian J. North 2 ,
  • Hiroyuki Inuzuka 2,6 ,
  • Xi He 4 ,
  • Yu Li , 1 ,
  • Jianping Guo , 2 ,
  • Xiangpeng Dai , 2
Expand
  • 1. School of Life Science and Technology, Harbin Institute of Technology, Harbin 150001, China
  • 2. Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
  • 3. Department of Biochemistry and Molecular Biology, Shanxi Medical University, Taiyuan 030001, China
  • 4. The FM Kirby Neurobiology Center, Children’s Hospital Boston, Harvard Medical School, Boston, MA 02115, USA
  • 5. 5Department of Oncology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang 453100, China
  • 6. 6Center for Advanced Stem Cell and Regenerative Research, Tohoku University Graduate School of Dentistry, Sendai 980-8575, Japan

Received date: 24 Oct 2017

Accepted date: 09 Jan 2018

Published date: 18 Oct 2018

Copyright

2018 The Author(s) 2018. This article is an open access publication

Abstract

Wnt signaling has emerged as a major regulator of tissue development by governing the self-renewal and maintenance of stem cells in most tissue types. As a key upstream regulator of the Wnt pathway, the transmembrane E3 ligase ZNRF3 has recently been established to play a role in negative regulation of Wnt signaling by targeting Frizzled (FZD) receptor for ubiquitination and degradation. However, the upstream regulation of ZNRF3, in particular the turnover of ZNRF3, is still unclear. Here we report that ZNRF3 is accumulated in the presence of proteasome inhibitor treatment independent of its E3-ubiquitin ligase activity. Furthermore, the Cullin 1-specific SCF complex containing β-TRCP has been identified to directly interact with and ubiquitinate ZNRF3 thereby regulating its protein stability. Similar with the degradation of β-catenin by β-TRCP, ZNRF3 is ubiquitinated by β-TRCP in both CKI-phosphorylation-and degron-dependent manners. Thus, our findings not only identify a novel substrate for β-TRCP oncogenic regulation, but also highlight the dual regulation of Wnt signaling by β-TRCP in a contextdependent manner where β-TRCP negatively regulates Wnt signaling by targeting β-catenin, and positively regulates Wnt signaling by targeting ZNRF3.

Key words: ZNRF3; β-TRCP; Wnt; ubiquitination; CKI

Cite this article

Yanpeng Ci , Xiaoning Li , Maorong Chen , Jiateng Zhong , Brian J. North , Hiroyuki Inuzuka , Xi He , Yu Li , Jianping Guo , Xiangpeng Dai . SCFβ-TRCP E3 ubiquitin ligase targets the tumor suppressor ZNRF3 for ubiquitination and degradation[J]. Protein & Cell, 2018 , 9(10) : 879 -889 . DOI: 10.1007/s13238-018-0510-2

1
Akhoondi S (2007) FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res 67:9006–9012

DOI

2
Behrens J (1998) Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science 280:596–599

DOI

3
Busino L (2003) Degradation of Cdc25A by beta-TrCP during S phase and in response to DNA damage. Nature 426:87–91

DOI

4
Clevers H (2006) Wnt/beta-catenin signaling in development and disease. Cell 127:469–480

DOI

5
de Bie P, Ciechanover A (2011) Ubiquitination of E3 ligases: selfregulation of the ubiquitin system via proteolytic and nonproteolytic mechanisms. Cell Death Differ 18:1393–1402

DOI

6
Espada J, Calvo MB, Diaz-Prado S, Medina V (2009) Wnt signalling and cancer stem cells. Clin Transl Oncol 11:411–427

DOI

7
Fuchs SY, Spiegelman VS, Kumar KG (2004) The many faces of beta-TrCP E3 ubiquitin ligases: reflections in the magic mirror of cancer. Oncogene 23:2028–2036

DOI

8
Gao D (2011) mTOR drives its own activation via SCF (betaTrCP)-dependent degradation of the mTOR inhibitor DEPTOR. Mol Cell 44:290–303

DOI

9
Goldstein B, Takeshita H, Mizumoto K, Sawa H (2006) Wnt signals can function as positional cues in establishing cell polarity. Dev Cell 10:391–396

DOI

10
Guardavaccaro D (2003) Control of meiotic and mitotic progression by the F box protein beta-Trcp1 in vivo. Dev Cell 4:799–812

DOI

11
Guo J (2016) pVHL suppresses kinase activity of Akt in a proline-hydroxylation-dependent manner. Science 353:929–932

DOI

12
Hao HX (2012) ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner. Nature 485:195–200

DOI

13
Hart M (1999) The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell. Curr Biol 9:207–210

DOI

14
Kimelman D, Xu W (2006) beta-catenin destruction complex: insights and questions from a structural perspective. Oncogene 25:7482–7491

DOI

15
Koo BK (2012) Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors. Nature 488:665–669

DOI

16
Kudo Y (2004) Role of F-box protein betaTrcp1 in mammary gland development and tumorigenesis. Mol Cell Biol 24:8184–8194

DOI

17
Lammi L (2004) Mutations in AXIN2 cause familial tooth agenesis and predispose to colorectal cancer. Am J Hum Genet 74:1043–1050

DOI

18
Lustig B (2002) Negative feedback loop of Wnt signaling through upregulation of conductin/axin2 in colorectal and liver tumors. Mol Cell Biol 22:1184–1193

DOI

19
MacDonald BT, He X (2012) Frizzled and LRP5/6 receptors for Wnt/beta-catenin signaling. Cold Spring Harb Perspect Biol 4:12

DOI

20
Morin PJ (1997) Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275:1787–1790

DOI

21
Nakayama K (2003) Impaired degradation of inhibitory subunit of NF-kappa B (I kappa B) and beta-catenin as a result of targeted disruption of the beta-TrCP1 gene. Proc Natl Acad Sci USA 100:8752–8757

DOI

22
Nusse R, Clevers H (2017) Wnt/beta-catenin signaling, disease, and emerging therapeutic modalities. Cell 169:985–999

DOI

23
Nusse R, Varmus HE (1982) Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 31:99–109

DOI

24
Peifer M, Polakis P (2000) Wnt signaling in oncogenesis and embryogenesis—a look outside the nucleus. Science 287:1606–1609

DOI

25
Rubinfeld B (1993) Association of the APC gene product with beta-catenin. Science 262:1731–1734

DOI

26
Rubinfeld B (1996) Binding of GSK3beta to the APC-betacatenin complex and regulation of complex assembly. Science 272:1023–1026

DOI

27
Saitoh T, Katoh M (2001) Expression profiles of betaTRCP1 and betaTRCP2, and mutation analysis of betaTRCP2 in gastric cancer. Int J Oncol 18:959–964

28
Sarikas A, Hartmann T, Pan ZQ (2011) The cullin protein family. Genome Biol 12:220

DOI

29
Scaglione KM (2007) SCF E3-mediated autoubiquitination negatively regulates activity of Cdc34 E2 but plays a nonessential role in the catalytic cycle in vitro and in vivo. Mol Cell Biol 27:5860–5870

DOI

30
Shen M, Schmitt S, Buac D, Dou QP (2013) Targeting the ubiquitinproteasome system for cancer therapy. Expert Opin Ther Targets 17:1091–1108

DOI

31
Shimizu K (2017) The SCFbeta-TRCP E3 ubiquitin ligase complex targets Lipin1 for ubiquitination and degradation to promote hepatic lipogenesis. Sci Signal. https://doi.org/10.1126/scisignal.aah4117

DOI

32
Skowyra D, Craig KL, Tyers M, Elledge SJ, Harper JW (1997) F-box proteins are receptors that recruit phosphorylated substrates to the SCF ubiquitin-ligase complex. Cell 91:209–219

DOI

33
Soucy TA (2009) An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458:732–736

DOI

34
Sparks AB, Morin PJ, Vogelstein B, Kinzler KW (1998) Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res 58:1130–1134

35
Spencer E, Jiang J, Chen ZJ (1999) Signal-induced ubiquitination of IkappaBalpha by the F-box protein Slimb/beta-TrCP. Genes Dev 13:284–294

DOI

36
Spranger S, Bao R, Gajewski TF (2015) Melanoma-intrinsic betacatenin signalling prevents anti-tumour immunity. Nature 523:231–235

DOI

37
Toomes C (2004) Spectrum and frequency of FZD4 mutations in familial exudative vitreoretinopathy. Invest Ophthalmol Vis Sci 45:2083–2090

DOI

38
Van Wesenbeeck L (2003) Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet 72:763–771

DOI

39
Wang Z, Liu P, Inuzuka H, Wei W (2014) Roles of F-box proteins in cancer. Nat Rev Cancer 14:233–247

DOI

40
Wang Z (2015) SCF(beta-TRCP) promotes cell growth by targeting PR-Set7/Set8 for degradation. Nat Commun 6:10185

DOI

41
Welcker M, Clurman BE (2008) FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer 8:83–93

DOI

42
Westbrook TF (2008) SCFbeta-TRCP controls oncogenic transformation and neural differentiation through REST degradation. Nature 452:370–374

DOI

43
Yang K (2017) Homeostatic control of metabolic and functional fitness of Treg cells by LKB1 signalling. Nature 548:602–606

DOI

Outlines

/